Renal amyloidosis in a patient with systemic lupus erythematosus

Elżbieta Semik-Grabarczyk¹, Marta Pietrukaniec¹, Henryk Karkosza², Hanna Wichary³, Jerzy Chudek³, Michał Holecki¹

¹ Department of Internal, Autoimmune and Metabolic Diseases, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
² Department of Nephrology, Transplantology and Internal Medicine, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
³ Department of Internal Diseases and Oncological Chemotherapy, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland

In March 2019, a 35-year-old man with obesity was referred to the hospital due to progressive weakness, laboratory abnormalities (anemia, leukopenia, increased serum creatinine levels), and fever (reduced by steroid treatment). His complaints started in 2006 with pneumonia, high fever accompanied by chills, and arthralgia of unknown origin. He had no family history of kidney or connective tissue diseases. Laboratory workup revealed serum positivity for anti-nuclear and anti-double-stranded DNA antibodies, leukopenia, thrombocytopenia, and hypergammaglobulinemia. Another episode of fever, arthralgia, anemia, leukopenia, and massive proteinuria (9 g/d) occurred in 2013. Between 2013 and 2019, due to recurrent fever, the patient periodically took glucocorticoids (prednisolone, 5 mg/d) prescribed by a general practitioner without consultation with a rheumatologist.

On examination, the patient was pale and had swollen lower extremities. His blood pressure was 160/90 mm Hg and heart rate was 110 bpm. Sonography revealed hepatosplenomegaly and portal hypertension. The length of the right and left kidney was 130 mm and 126 mm, respectively, and both organs showed marked hyperechogenicity. Laboratory examination indicated impaired renal function (serum creatinine, 2.53 mg/dl; estimated glomerular filtration rate, 30 ml/min/1.73 m²), proteinuria of up to 3.8 g/d, anemia (hemoglobin, 7 g/dl), a white blood cell count of 4710/µl, and a platelet count of 14.8 × 10⁴/µl. Serum complement components were normal (C₃, 141 mg/dl [reference range, 90–180 mg/dl]; C₄, 35 mg/dl [reference range, 10–40 mg/dl]). The patient tested positive for antinuclear and anti-ribosomal P protein antibodies (titer, 1:3200), but negative for anti–double-stranded DNA and antineutrophil cytoplasmic antibodies. He had decreased levels of serum albumin (2.5 g/dl) and slightly elevated levels of C-reactive protein (39 mg/l).

The patient’s clinical presentation was typical of lupus nephritis (he met the American Rheumatism Association criteria for systemic lupus erythematosus [SLE] both in 2006 [≥6] and 2013 [≥5]). During hospitalization at our department, renal biopsy was performed, followed by an immediate intravenous administration of methylprednisolone (500 mg/d for 3 days), and then by oral prednisone. Surprisingly, histologic examination showed no features of lupus nephritis but was suggestive of amyloidosis (FIGURE 1A–10). Finally, the patient discontinued glucocorticoid therapy and underwent additional tests, which allowed for the diagnosis of AA amyloidosis. Plasma cell dyscrasia was excluded based on the results of peripheral blood flow cytometry (CD19⁺ B cells, CD20⁺ B cells, lambda/kappa ratio of 1.21).

Amyloidosis is a well-known complication of chronic inflammatory and connective tissue diseases. However, its association with SLE is extremely rare (there have been fewer than 40 cases reported since 1956). One of the causes may be a low level of serum amyloid A in the course of active lupus (not measured in our patient). It seems that a persistent, long-lasting elevation of the serum amyloid A is needed for the development of AA amyloidosis.

In this case, AA amyloidosis developed acutely with the symptoms of nephrotic syndrome in a patient who was finally diagnosed with SLE, but with a 13-year delay. In our opinion, the major reason for the development of amyloidosis was long-lasting inflammation, treated ineffectively with glucocorticoids in an undiagnosed patient. Of note, the period of time between the diagnoses of SLE and amyloidosis may vary from 1 year to 35 years. We suggest that amyloidosis, although uncommon, should be considered in the differential diagnosis of proteinuria in patients with SLE.
FIGURE 1 Renal biopsy specimen (magnification × 200): A, C – periodic acid-Schiff (PAS) stain; B, D – Congo red stain. Renal biopsy revealed global sclerosis of the most glomeruli. The capillary walls in the nonsclerotic glomeruli were not thickened and no double contouring was observed. The extracellular matrix (ECM) in the mesangial area was expanded and stained positive for amyloid (B, D), similarly to the ECM in glomeruli with global sclerosis: blue arrows indicate the deposits of an amorphous extracellular mass in the sclerotic (A) and nonsclerotic (C) glomeruli. Amyloid deposits can be noted (B, D). A significant hypertrophy of a nonsclerotic glomerulus (C), intratubular PAS-positive deposits (A, asterisks), and an amorphous mass in the lumen of the arterial vessel (A, B, white arrows) were also observed. No extracapillary proliferation was present. Severe tubular atrophy with expansion of the connective tissue and scattered mononuclear cells was detected in the tubulointerstitial compartment. The arterial walls were slightly thickened, without inflammatory infiltrates, but with an amorphous substance that stained positive with Congo red (B, D). Immunohistochemistry was negative for immunoglobulins IgA, IgG, and IgM.

ARTICLE INFORMATION

CONFLICT OF INTEREST None declared.

OPEN ACCESS This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only. For commercial use, please contact the journal office at pamw@mp.pl.


REFERENCES